1 / 8

Efficacy of Ru-106 Plaque Brachytherapy for Ocular Surface Squamous Neoplasia Management

This study evaluates the outcomes of ruthenium-106 (Ru-106) plaque brachytherapy in treating ocular surface squamous neoplasia (OSSN) over a period from January 2004 to December 2009. With a cohort of 21 patients (mean age 49.28 years), the study highlights that this intervention is effective in managing residual or recurrent OSSN, achieving good tumor control and preserving ocular function. Complications included scleral necrosis and corneal epithelial defects, but overall, Ru-106 brachytherapy demonstrates a promising approach for successful treatment of OSSN.

celine
Télécharger la présentation

Efficacy of Ru-106 Plaque Brachytherapy for Ocular Surface Squamous Neoplasia Management

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. OUTCOME OF PLAQUE BRACHYTHERAPY IN OCULAR SURFACE SQUAMOUS NEOPLASIA (OSSN) Surbhi D Joshi1, Santosh G Honavar1, Manju Meena1, Milind N Naik1, Geeta K Vemuganti2, Vijay Anand P Reddy3 1 Department of Ocular Oncology,LV Prasad eye Institute, Hyderabad.2 Department of Ophthalmic Pathology, LV Prasad eye Institute, Hyderabad.3 Department of Radiation Oncology, Apollo Cancer Hospital, Hyderabad.

  2. I have no financial interests or relationships to disclose Financial Disclosure

  3. Introduction • Commonest ocular surface tumor in Asia • Excision + cryotherapy : Recurrence rate <5% • Factors affecting recurrence • Residual tumor • Aggressive HPE variant • Systemic factors (HIV, Xeroderma Pigmentosa) • Episcleral radiation : Plaque Brachytherapy • Promising Results • Organ and function salvage

  4. Study Method • Prospective interventional case series • January 2004- December2009 Study Aim • To evaluate Ru-106 plaque brachytherapy in the management of OSSN

  5. Demographics & Treatment Details • Total patients: 21 • Males: 12 • Mean Age: 49.28 • (range, 33-71)yrs • Indications for Episcleral Plaque: • Residual (Excision base + on HPE) • Recurrent Ru-106 Round Plaque for all patients Minimum follow up: 1 year Maximum follow up: 6 years

  6. Episcleral fixity & UBM • On clinical examination episcleral fixity was noted in 10(47.6%) patients • On UBM, suspicious scleral involvement was seen in 5 patients

  7. Results • Complications : • Scleral necrosis -1 • Corneal epithelial defect – 1 • Recurrence Management : • Enucleation • Exenteration 19.1% PRE HPE POST

  8. Conclusions • Ru-106 plaque brachytherapy is a safe & effective option in the management of residual or recurrent OSSN with scleral infiltration • It provides for good tumor control, & eye & vision salvage

More Related